ClinicalTrials.gg
CompletedNCT00550745Updated Apr 12, 2017Results posted

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

A Phase 4 interventional study of Zoster Vaccine, Live and Comparator: placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11,999
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
2nd of 29
11,999 · median 160
Started
2007
with 3 others
Phase 4
8 of 29
none open now
Registered
6th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 2nd largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 4, and was the 6th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 60+ years of Age
  • Signed an prior to the start of study
  • Non-Feverish, (less than 101.0°F / 38.3°C) on day of vaccination
  • Females must be or have a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • A history of allergic reaction to any vaccine component (including gelatin or neomycin)
  • Prior receipt of any varicella or zoster vaccine
  • Any administered within 4 weeks before the start of the study or scheduled during the 42 days after vaccination
  • Any inactivated virus vaccine, except for flu vaccine, administered within 7 days before the start of the study or scheduled during the 42 days after vaccination
  • Subject is pregnant or breastfeeding
  • Participation in an drug or vaccine study within the last 30 days prior to the start of the study or expected during the 42 days after vaccination
  • An ongoing illness (including active untreated tuberculosis) that might interfere with or prevent the subject from completion of the study
  • Use of therapy. Subjects taking such as prednisone should be excluded. Excluded immunosuppressive therapies also include chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation
  • Known or suspected immune dysfunction that is caused by a medical condition or any other cause. Examples of medical conditions associated with immune dysfunction include congenital immunodeficiency, (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized . Subjects with a history of cancer who are not on active treatment and are not thought to have a weakened immune system at the time of enrollment will be eligible
  • Any active use of non-topical antiviral therapy including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
11,999 participants (actual)

Study arms

  • Experimental
    1

    Arm 1: vaccine

    Biological: Zoster Vaccine, Live

  • Placebo comparator
    2

    Arm 2: Placebo Comparator

    Biological: Comparator: placebo

Interventions

  • single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.

  • BiologicalComparator: placebo

    single 0.65 mL Placebo injection. 6 month treatment period.

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events Reported Within 42 Days Postvaccination

    Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

    Time frame: 42 Days

Secondary outcomes

  1. Serious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination

    Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

    Time frame: 6 months

07

Results

Posted Feb 2, 2010

Participant flow

Phase IV First subject enrolled on 17-Sep-2007. Last subject enrolled on 19-Jun-2008. The last subject's last visit was 15-Jan-2009. The study was conducted at 46 study centers throughout the United States, Canada, Germany, Spain, and United Kingdom.

Participant flow — Overall Study
MilestoneZOSTAVAX™Placebo
Started60005999
Completed59135939
Not completed8760
Withdrew: Death2016
Withdrew: Lost to follow-up4530
Withdrew: Physician decision02
Withdrew: Protocol violation42
Withdrew: Withdrawal by subject1710
Withdrew: Screen failure10

Outcome measures

PrimarySerious Adverse Events Reported Within 42 Days Postvaccination

Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

Time frame:
42 Days
Reported as:
Number · Participants
Serious Adverse Events Reported Within 42 Days Postvaccination
ParticipantsZOSTAVAX™Placebo
Serious Adverse Events (AEs)8467
Serious AEs deemed vaccine-related by investigator20
Death65
Statistical analysis
  • ZOSTAVAX™ vs Placebo · Risk ratio (rr): 1.26 · 95% CI 0.91 to 1.73Relative risk (ZOSTAVAX™/placebo) of proportion of subjects reporting ≥ 1 serious AE through 42 Days postvaccination and 95% Confidence Interval were based on Miettinen and Nurminen \[Comparative analysis of two rates. Stat Med 1985;4:213-26\] method.
SecondarySerious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination

Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement.

Time frame:
6 months
Reported as:
Number · Participants
Serious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination
ParticipantsZOSTAVAX™Placebo
Serious AEs340300
Serious AEs deemed vaccine-related by investigator21
Death2417
Statistical analysis
  • ZOSTAVAX™ vs Placebo · Risk ratio (rr): 1.13 · 95% CI 0.98 to 1.32Relative risk (ZOSTAVAX™/placebo) of proportion of subjects reporting ≥ 1 serious AE through 6 months postvaccination and 95% Confidence Interval were based on Miettinen and Nurminen \[Comparative analysis of two rates. Stat Med 1985;4:213-26\] method.

Adverse events

Collected over Serious AEs reported within 6 months (182 days) postvaccination. Only Serious adverse events were collected in this study. The "Other Adverse Events" table is not applicable for this study and shows "0/0" for " participants affected/at risk". Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOSTAVAX™—340/5,979 (5.7%)—
Placebo—300/5,990 (5%)—
Most frequent serious events
Showing 10 of 386
Most frequent serious events
EventZOSTAVAX™Placebo
Atrial fibrillationCardiac disorders21/597914/5990
Chest painGeneral disorders12/597917/5990
PneumoniaInfections and infestations16/597913/5990
Coronary artery diseaseCardiac disorders11/597915/5990
OsteoarthritisMusculoskeletal and connective tissue disorders14/597910/5990
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)14/59798/5990
Myocardial infarctionCardiac disorders8/597914/5990
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/59797/5990
Renal failure acuteRenal and urinary disorders12/59792/5990
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders8/597911/5990

Baseline characteristics

Age, Continuous
Age, Continuous(years)ZOSTAVAX™PlaceboTotal
Mean70.5 ± 7.570.4 ± 7.670.5 ± 7.5
Age, Customized
Age, Customized(participants)ZOSTAVAX™PlaceboTotal
60 to 69 Years of Age309231136205
70 to 79 Years of Age199419863980
≥ 80 Years of Age8978981795
Sex: Female, Male
Sex: Female, Male(Participants)ZOSTAVAX™PlaceboTotal
Female351535257040
Male246824724940
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ZOSTAVAX™PlaceboTotal
Black10985194
White5759577011529
Other115142257
Region
Region(Participants)ZOSTAVAX™PlaceboTotal
U.S.5309531210621
Non-U.S.6746851359
Type of Residence
Type of Residence(Participants)ZOSTAVAX™PlaceboTotal
Assisted Living176162338
Independent Residential5790582111611
Nursing Home171431
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS, Annunziato PW, Parrino J. Safety and tolerability of zoster vaccine in adults >/=60 years old. Hum Vaccin. 2011 Nov;7(11):1130-6. doi: 10.4161/hv.7.11.17982. Epub 2011 Nov 1. PubMed 22048110 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2007
First posted
Oct 30, 2007
Start
Sep 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Feb 2, 2010
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00550745
Responsible party
Sponsor
First posted
Oct 30, 2007
Start date
Sep 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Feb 2, 2010
Last update
Apr 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion